Skip to main content
Premium Trial:

Request an Annual Quote

Biocrates, Chenomx in Metabolic Profiling Technologies Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Austrian biomarker firm Biocrates and Canadian firm Chenomx have signed a co-marketing pact, under which the firms will combine their technologies to generate metabolic profiling tools for monitoring the effects of disease, nutrition, toxins, environment, or drugs on an organism.

Biocrates has developed a mass spectrometry-based platform, while Chenomx uses a unique methodology based on nuclear magnetic resonance spectroscopy to analyze biological samples. The firms said that by co-marketing their technologies they will be able to offer complementary metabolomic analyses, service a large common customer base, and jointly promote the use of each other's services.

"The two methods produce complementary data sets with very little overlap in results," Chenomx CEO Neil Taylor said in a statement. "Both tests can be run on the same samples thus offering a more comprehensive profile."

Biocrates has already brought to market a kit for metabolomics, which it will now evaluate and optimize on Chenomx's instrumentation and software.

Further terms of the alliance were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.